Iyo M - Search Results

1

Nine- or fewer repeat alleles in VNTR polymorphism of the dopamine transporter gene is a strong risk factor for prolonged methamphetamine psychosis.

Ujike H, Harano M, Inada T, Yamada M, Komiyama T, Sekine Y, Sora I, Iyo M, Katsu T, Nomura A, Nakata K, Ozaki N. Ujike H, et al. Among authors: iyo m. Pharmacogenomics J. 2003;3(4):242-7. doi: 10.1038/sj.tpj.6500189. Pharmacogenomics J. 2003. PMID: 12931138

2

Suppression of oro-facial movements by rolipram, a cAMP phosphodiesterase inhibitor, in rats chronically treated with haloperidol.

Sasaki H, Hashimoto K, Inada T, Fukui S, Iyo M. Sasaki H, et al. Among authors: iyo m. Eur J Pharmacol. 1995 Aug 25;282(1-3):71-6. doi: 10.1016/0014-2999(95)00278-s. Eur J Pharmacol. 1995. PMID: 7498291

3

The effects of a selective cAMP phosphodiesterase inhibitor, rolipram, on methamphetamine-induced behavior.

Iyo M, Maeda Y, Inada T, Kitao Y, Sasaki H, Fukui S. Iyo M, et al. Neuropsychopharmacology. 1995 Aug;13(1):33-9. doi: 10.1016/0893-133X(94)00133-K. Neuropsychopharmacology. 1995. PMID: 8526969

4

Prevention of methamphetamine-induced behavioral sensitization in rats by a cyclic AMP phosphodiesterase inhibitor, rolipram.

Iyo M, Bi Y, Hashimoto K, Inada T, Fukui S. Iyo M, et al. Eur J Pharmacol. 1996 Sep 26;312(2):163-70. doi: 10.1016/0014-2999(96)00479-7. Eur J Pharmacol. 1996. PMID: 8894591

5

Does an increase of cyclic AMP prevent methamphetamine-induced behavioral sensitization in rats?

Iyo M, Bi Y, Hashimoto K, Tomitaka SI, Inada T, Fukui S. Iyo M, et al. Ann N Y Acad Sci. 1996 Oct 31;801:377-83. doi: 10.1111/j.1749-6632.1996.tb17458.x. Ann N Y Acad Sci. 1996. PMID: 8959050 No abstract available.

6

Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: compartment analysis for beta-CFT binding with positron emission tomography.

Ouchi Y, Yoshikawa E, Okada H, Futatsubashi M, Sekine Y, Iyo M, Sakamoto M. Ouchi Y, et al. Among authors: iyo m. Ann Neurol. 1999 May;45(5):601-10. Ann Neurol. 1999. PMID: 10319882

7

Methamphetamine-associated obsessional symptoms and effective risperidone treatment: a case report.

Iyo M, Sekine Y, Matsunaga T, Tsukamoto T, Takei N, Mori N. Iyo M, et al. J Clin Psychiatry. 1999 May;60(5):337-8. doi: 10.4088/jcp.v60n0512d. J Clin Psychiatry. 1999. PMID: 10362445 No abstract available.

8

Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET.

Sekine Y, Iyo M, Ouchi Y, Matsunaga T, Tsukada H, Okada H, Yoshikawa E, Futatsubashi M, Takei N, Mori N. Sekine Y, et al. Among authors: iyo m. Am J Psychiatry. 2001 Aug;158(8):1206-14. doi: 10.1176/appi.ajp.158.8.1206. Am J Psychiatry. 2001. PMID: 11481152

9

The effects of FK506, a specific calcineurin inhibitor, on methamphetamine-induced behavioral change and its sensitization in rats.

Tsukamoto T, Iyo M, Tani K, Sekine Y, Hashimoto K, Ohashi Y, Suzuki K, Iwata Y, Mori N. Tsukamoto T, et al. Among authors: iyo m. Psychopharmacology (Berl). 2001 Nov;158(2):107-13. doi: 10.1007/s002130100870. Psychopharmacology (Berl). 2001. PMID: 11702083

10

Yohimbine increases the binding potential for [11C]flumazenil in the monkey brain.

Matsunaga T, Tsukada H, Nishiyama S, Sekine Y, Kakiuchi T, Iyo M, Mori N. Matsunaga T, et al. Among authors: iyo m. J Neural Transm (Vienna). 2001;108(12):1375-82. doi: 10.1007/s007020100014. J Neural Transm (Vienna). 2001. PMID: 11810402

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

449 results

Search Page

Filters